AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11405514
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (30 mg x day(-1))
Trial: 9514183
Drug: MO/HCTZ 3.75/6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MO/HCTZ 3.75/6.25 mg once daily
Trial: 30137242
Drug: Protease inhibitor-based
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-based regimens
Trial: 24116356
Drug: MCBA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCBA + 5.6 mL of rhBMP‐2/ACS (8.4 mg of rhBMP‐2)
Trial: 24116356
Drug: MCBA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCBA + 2.8 mL of rhBMP‐2/ACS (4.2 mg of rhBMP‐2)
Trial: 21951654
Drug: Single intraarticular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraarticular injection of 40 mg triamcinolone
Trial: 21951654
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of 40 mg triamcinolone at 21‐day interval
Trial: 19469115
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA) with 10 mL of 0.5% bupivacaine before and at the end of surgery
Trial: 19469115
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral analgesia (TPVA) with 30 mL of 0.5% bupivacaine before and 15 mL at the end of surgery
Trial: 17545082
Drug: Podophyllotoxin solid
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin solid lipid nanoparticle gel
Trial: 17545082
Drug: Routine podophyllotoxin
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine podophyllotoxin gel preparation
Trial: 8468105
Drug: Carleton Skill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carleton Skill Training Program (CSTP) to increase hypnotic susceptibility
Trial: 3514908
Drug: Butoconazole vaginal
RxNorm normalized name: butoconazole Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butoconazole vaginal suppositories, 100 mg/day
Trial: 3514908
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal tablets, 200 mg/day
Trial: 20435293
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of dexketoprofen
Trial: 20435293
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL intrauterine 2% lidocaine
Trial: 19115153
Drug: Alverine citrate
RxNorm normalized name: alverine citrate
DrugBank: Alverine (DB01616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alverine citrate plus simethicone (60 mg alverine citrate + 300 mg simethicone)
Trial: 12364840
Drug: Attachment-based family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-based family therapy (ABFT) for 12 weeks
Trial: 10472854
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 0.025 mg/day
Trial: 10472854
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 0.05 mg/day
Trial: 10472854
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 0.06 mg/day
Trial: 10472854
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 0.1 mg/day
Trial: 8752759
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of pure oxygen (O2) during EIS
Trial: 8752759
Drug: No inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inhalation of pure oxygen (O2) during EIS
Trial: 6401230
Drug: Nitroglycerin (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (0.8 mg sublingually)
Trial: 6401230
Drug: Metoprolol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.15 mg/kg i.v.)
Trial: 26773321
Drug: Homeopathic complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic complex (6cH each of Arnica montana, Bryonia alba, Causticum, Kalmia latifolia, Rhus toxicodendron, and Calcarea fluorica) plus standard physiotherapy (massage, thermal therapy, joint mobilization) every 2 weeks
Trial: 26773321
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard physiotherapy (massage, thermal therapy, joint mobilization) every 2 weeks
Trial: 24589127
Drug: Liraglutide plus
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide plus insulin (LIRA)
Trial: 24589127
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin only (controls)
Trial: 16286056
Drug: Inhaled zanamivir
RxNorm normalized name: zanamivir Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled zanamivir 10 mg once daily for 14 days
Trial: 7491655
Drug: Acetazolamide (ACZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACZ) 1 to 1.6 g intravenously
Trial: 1968731
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (0.05 microgram/kg body weight/minute for 120 minutes) with placebo pretreatment
Trial: 1968731
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion with atenolol pretreatment (beta-1-selective blocker)
Trial: 1968731
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion with propranolol pretreatment (nonselective beta blocker)
Trial: 1968731
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion with ICI 118551 pretreatment (beta-2-selective blocker)
Trial: 1968731
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion with different pretreatments
Trial: 387542
Drug: Vincristine, methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine, methotrexate, cyclophosphamide, and 5-fluorouracil (initiation course) followed by mitomycin-C with 5-fluorouracil (maintenance therapy)
Trial: 22221684
Drug: IAADS (Improved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAADS (Improved Anesthetic Agent Delivery System)
Trial: 15474248
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C vaginal tablets (250 mg) once a day for 6 days
Trial: 15474248
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C vaginal tablets
Trial: 8202898
Drug: Flurbiprofen 200
RxNorm normalized name: flurbiprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 200 mg
Trial: 11121916
Drug: Aspirin 2600
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 2600 mg
Trial: 2787809
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and antacids (added after severe injuries)
Trial: 557318
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg subcutaneous physostigmine therapy (three sessions)
Trial: 557318
Drug: Control injections
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control injections (randomly interspersed sessions)
Trial: 31699568
Drug: hs-CRP ≥0.74
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP ≥0.74 mg/L at 3 months
Trial: 25497995
Drug: Omalizumab (225-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (225-300 mg every 2 weeks)
Trial: 25497995
Drug: Omalizumab (every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (every 4 weeks dosing regimen)
Trial: 25497995
Drug: Omalizumab (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (higher or lower doses)
Trial: 17351987
Drug: Anthroposophy art
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthroposophy art therapy (painting with water-based paints)
Trial: 15353002
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g alcohol per day
Trial: 15353002
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g alcohol per day
Trial: 29374350
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg mixed in 100 ml normal saline)
Trial: 29374350
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 ml normal saline only)
Trial: 23007732
Drug: Clamp-crushing parenchyma
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clamp-crushing parenchyma transection (CC-PT)
Trial: 17784972
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) administered over six weekly sessions
Trial: 17784972
Drug: Delayed cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed cognitive-behavioural therapy (D-CBT) administered twice weekly over three weeks
Trial: 14996630
Drug: Oral antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiplatelet and antithrombotic therapies
Trial: 12056242
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy using five different protocols
Trial: 9931764
Drug: Electrostimulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulation therapy
Trial: 2686259
Drug: 4 mg/h
RxNorm normalized name: estradiol 0.00104 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/h of ISDN
Trial: 27859533
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment-based approach (ART-based)
Trial: 25727953
Drug: 0.5‐h infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐h infusion of 0.5 g of imipenem every 6 h for 8 doses
Trial: 25727953
Drug: 4‐h infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐h infusion of 0.5 g of imipenem every 6 h for 8 doses
Trial: 25727953
Drug: 4‐h infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐h infusion of 1 g of imipenem every 6 h
Trial: 25727953
Drug: 0.5‐h infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐h infusion of 1 g of imipenem every 6 h
Trial: 25727953
Drug: All simulated
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All simulated regimens (4‐h infusion)
Trial: 23478070
Drug: Lansoprazole (LPZ)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LPZ) 15mg once daily
Trial: 23478070
Drug: Gefarnate (GFN)
RxNorm normalized name: Guaifenesin
DrugBank: Gefarnate (DB12079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefarnate (GFN) 50mg twice daily
Trial: 19317378
Drug: Ramelteon 8
RxNorm normalized name: ramelteon 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg at bedtime for 10 weeks
Trial: 19317378
Drug: Ramelteon 8
RxNorm normalized name: ramelteon 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg at bedtime
Trial: 17162041
Drug: Pelvicol porcine
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pelvicol porcine collagen implant
Trial: 17162041
Drug: No implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No implant (control group)
Trial: 7843479
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (elemental calcium 156 or 312 mg/day per os) and vitamin D3 (0.5 micrograms/3 day per os)
Trial: 25772974
Drug: Web-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based intervention (PA website and monthly tailored emails)
Trial: 25772974
Drug: Mixed intervention
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed intervention (combination of web- and center-based)
Trial: 15007374
Drug: Lidocaine instillation
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine instillation enhanced by electromotive drug administration (EMDA)
Trial: 9893772
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous antibiotic therapy with cefamandole 1 g i.v. every 6 h for 7 days
Trial: 9893772
Drug: Abbreviated intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated intravenous therapy with cefamandole (1 g i.v. every 6 h for 2 days) followed by oral therapy with cefaclor (500 mg every 8 h for 5 days)
Trial: 8031068
Drug: Antacids in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids in didanosine tablets
Trial: 8031068
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 300 mg isoniazid
Trial: 2544345
Drug: Naloxone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (all doses)
Trial: 25894531
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 400 μg of salbutamol
Trial: 17346304
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (150 mg/day), n = 34
Trial: 12016602
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg hyperbaric bupivacaine
Trial: 2007107
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg hyperbaric bupivacaine
Trial: 12016602
Drug: 10.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mg hyperbaric bupivacaine
Trial: 12016602
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg hyperbaric bupivacaine
Trial: 10440603
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg three times daily
Trial: 10440603
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg twice daily
Trial: 16431305
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg twice daily
Trial: 2186587
Drug: Single infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of 8 g fosfomycin and 1 g metronidazole at induction of anaesthesia (Group 1)
Trial: 2186587
Drug: Bacitracin 250
RxNorm normalized name: Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacitracin 250 mg plus neomycin 250 mg (as four tablets on three occasions over two days), metronidazole 500 mg tablets three times a day for one day, and ampicillin 1 g intravenously at induction of anaesthesia (Group 2)
Trial: 6243242
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cyclophosphamide, methotrexate, vincristine) and radiation therapy
Trial: 6243242
Drug: Cyclophosphamide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide and radiation therapy
Trial: 24187863
Drug: Jianjining granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianjining granules and Western Medicine (prednisone or pyridostigmine bromide)
Trial: 17824291
Drug: Eprosartan (477.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (477.5 +/- 143.7 mg/d)
Trial: 17824291
Drug: Telmisartan (65.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (65.9 +/- 17.7 mg)
Trial: 17824291
Drug: Candesartan (11.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (11.9 +/- 4.0 mg)
Trial: 17824291
Drug: No sartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sartan treatment (Control group)
Trial: 15232456
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (two-dose regime)
Trial: 11686355
Drug: Once-daily low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily low molecular weight heparin
Trial: 11686355
Drug: Twice-daily low
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily low molecular weight heparin
Trial: 9645829
Drug: Chlorthalidone (12.5-25.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5-25.0 mg/d) with the addition of atenolol (25-50 mg/d) or reserpine (0.05-0.10 mg/d) if needed
Trial: 9645829
Drug: Chlorthalidone (12.5-25.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5-25.0 mg/d)
Trial: 24919887
Drug: 75 μg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 μg of desogestrel/die for 5 weeks
Trial: 24919887
Drug: 100 mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of danazol/die for 5 weeks
Trial: 15998708
Drug: Powdered North
RxNorm normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered North American ginseng (3 g)
Trial: 7735418
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (0.15 mg/kg per dose)
Trial: 1675029
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of purified gonococcal pilus vaccine given intradermally on day 1 and day 14
Trial: 24602167
Drug: Non-restorative caries
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-restorative caries treatment (NRCT)
Trial: 21457202
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg subcutaneously at baseline followed by 40 mg every other week for 12 weeks
Trial: 21457202
Drug: Placebo (identical-looking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical-looking injections with no active ingredient)
Trial: 16843806
Drug: Nonabsorbable suture
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonabsorbable suture anchor (G II, DePuy Mitek)
Trial: 12969091
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (rabeprazole 20 mg b.d., amoxicillin 1 g b.d. for 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 500 mg b.d., and tinidazole 500 mg b.d. for 5 days)
Trial: 12969091
Drug: Low-dose therapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose therapy (rabeprazole 20 mg b.d., amoxicillin 1 g b.d. for 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 250 mg b.d., and tinidazole 500 mg b.d. for 5 days)
Trial: 8406151
Drug: SMS 201‐995
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS 201‐995 (25 micrograms subcutaneously three times daily)
Trial: 8406151
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg once a day)
Trial: 8406151
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of SMS 201‐995 and omeprazole
Trial: 3530612
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 20 m‐units min‐1 m‐2
Trial: 3530612
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 80 m‐units min‐1 m‐2
Trial: 3530612
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 200 m‐units min‐1 m‐2
Trial: 3530612
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at all three rates
Trial: 3530612
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at all three doses
Trial: 27173100
Drug: Tecarfarin (CYP2C9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecarfarin (CYP2C9 interacting drugs)